For example, research on heterozygous loss‐of‐function mutations in granulin (GRN) associated with frontotemporal lobar degeneration (FTLD) has shown how peripheral immune responses can affect CNS pathology, suggesting potential therapeutic targets for AD. This evidence concerns the gene GRN and Alzheimer disease.